Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
Brand Name | Status | Last Update |
---|---|---|
animi-3 | unapproved drug other | 2013-02-06 |
animi-3 with vitamin d | unapproved drug other | 2011-05-23 |
bp vit 3 | unapproved drug other | 2023-10-11 |
c-nate dha | unapproved drug other | 2024-01-22 |
citranatal assure | unapproved drug other | 2024-01-08 |
citranatal dha | unapproved drug other | 2020-07-28 |
citranatal essence | unapproved drug other | 2020-07-07 |
enbrace hr | unapproved drug other | 2025-01-02 |
enlyte | unapproved drug other | 2022-07-01 |
icosapent | ANDA | 2024-01-24 |
Expiration | Code | ||
---|---|---|---|
ICOSAPENT ETHYL, ICOSAPENT ETHYL, TEVA PHARMS USA | |||
2023-03-08 | PC |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Icosapent Ethyl, Vascepa, Amarin Pharms | |||
9603826 | 2033-06-28 | U-2696 | |
9610272 | 2033-06-28 | U-2697 | |
9623001 | 2033-06-28 | U-2698 | |
9693984 | 2033-06-28 | U-2697 | |
9693985 | 2033-06-28 | U-2696 | |
9693986 | 2033-06-28 | U-2698 | |
9918954 | 2033-06-28 | U-2699 | |
10278935 | 2033-06-28 | U-2701 | |
10278936 | 2033-06-28 | U-2702 | |
10278937 | 2033-06-28 | U-2703 | |
10383840 | 2033-06-28 | U-2704 | |
10555924 | 2033-06-28 | U-2743 | |
10555925 | 2033-06-28 | U-2744 | |
10568861 | 2033-06-28 | U-2756 | |
10576054 | 2033-06-28 | U-2762 | |
10668042 | 2033-06-28 | U-2841 | |
10786478 | 2033-06-28 | U-2959, U-2960 | |
10792270 | 2033-06-28 | U-2962 | |
10894028 | 2033-06-28 | U-3053 | |
11000499 | 2033-06-28 | U-3126 | |
11116742 | 2033-06-28 | U-3221 | |
11298333 | 2033-06-28 | U-3358 | |
11369582 | 2033-06-28 | U-2841 | |
8410086 | 2030-06-15 | U-2688 | |
8455472 | 2030-06-15 | U-2690 | |
8669245 | 2030-06-15 | U-2694 | |
8710041 | 2030-06-15 | U-2690 | |
10842768 | 2030-06-15 | U-2688 | |
8298554 | 2030-04-29 | DP | |
8445003 | 2030-04-29 | U-1287 | |
8445013 | 2030-04-29 | U-1287 | |
8454994 | 2030-04-29 | U-2689 | |
8501225 | 2030-04-29 | U-1287 | |
8551521 | 2030-04-29 | U-1287 | |
8563608 | 2030-04-29 | U-1287 | |
8617593 | 2030-04-29 | U-1287, U-1478, U-2691 | |
8617594 | 2030-04-29 | U-1287 | |
8618166 | 2030-04-29 | U-2689 | |
8623406 | 2030-04-29 | U-1287, U-1478, U-2692 | |
8642077 | 2030-04-29 | U-2693 | |
8691871 | 2030-04-29 | U-2689 | |
8703185 | 2030-04-29 | U-2691 | |
8709475 | 2030-04-29 | U-2689 | |
10010517 | 2030-04-29 | U-2690 | |
10265287 | 2030-04-29 | U-2700 | |
10792267 | 2030-04-29 | U-2961 | |
10842766 | 2030-04-29 | U-2997 | |
10881632 | 2030-04-29 | U-3052 | |
11103477 | 2030-04-29 | U-3209 | |
11154526 | 2030-04-29 | U-3240 | |
11213504 | 2030-04-29 | U-3292 | |
11717504 | 2030-04-29 | U-3669 | |
8399446 | 2030-02-09 | U-1287 | |
8415335 | 2030-02-09 | U-1287 | |
8426399 | 2030-02-09 | U-1287 | |
8431560 | 2030-02-09 | U-1287 | |
8440650 | 2030-02-09 | U-1287 | |
8518929 | 2030-02-09 | U-1287 | |
8524698 | 2030-02-09 | U-1287 | |
8546372 | 2030-02-09 | U-1287 | |
8680144 | 2030-02-09 | U-2695 | |
9198892 | 2027-09-25 | U-2706 | |
9700537 | 2027-05-31 | U-2707 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | — | 3 | — | — | 3 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
Huntington disease | D006816 | Orphanet_399 | G10 | — | — | 1 | — | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | 1 | — | — | 1 |
Colonic neoplasms | D003110 | — | C18 | — | — | 1 | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dyslipidemias | D050171 | — | — | 1 | — | — | — | — | 1 |
Lipid metabolism disorders | D052439 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Icosapent |
INN | icosapent |
Description | All-cis-5,8,11,14,17-icosapentaenoic acid is an icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17. It has a role as a nutraceutical, a micronutrient, an antineoplastic agent, an antidepressant, a Daphnia galeata metabolite, a mouse metabolite, an anticholesteremic drug and a fungal metabolite. It is an icosapentaenoic acid and an omega-3 fatty acid. It is a conjugate acid of an all-cis-5,8,11,14,17-icosapentaenoate. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O |
PDB | — |
CAS-ID | 10417-94-4 |
RxCUI | — |
ChEMBL ID | CHEMBL460026 |
ChEBI ID | 28364 |
PubChem CID | 446284 |
DrugBank | DB00159 |
UNII ID | AAN7QOV9EA (ChemIDplus, GSRS) |